TP53 and cancer: IL-6 has tumour-promoting behaviours which include downregulating the expression and activity of TP53 through increased TP53 protein degradation which results in enhanced evasion of growth suppression [32], cell death resistance [33,34], cancer cell self-renewal [35,36], and helping with tumour invasion and metastasis [[37], [38], [39]].